Trulicity Complete Drug-Drug Interaction Profile (Dulaglutide)

How Dulaglutide Works: The Mechanism Behind Its Interactions

Dulaglutide is a GLP-1 receptor agonist fused to a modified human IgG4 Fc fragment, giving it a half-life of approximately 5 days and allowing once-weekly dosing [1]. Understanding the receptor-level and physiological actions of dulaglutide is essential before mapping its interaction profile, because most interactions trace back to one of two mechanisms: slowed gastric emptying or additive blood-glucose lowering.

GLP-1 Receptor Activation and Insulin Secretion

GLP-1 receptors are expressed on pancreatic beta cells, the vagus nerve, and the gastric wall. When dulaglutide binds these receptors, it stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying [2]. The glucose-dependence of insulin secretion is the reason monotherapy carries a low intrinsic hypoglycemia risk. Problems arise when dulaglutide is combined with agents that lower glucose independently of glucose concentration, namely insulin and sulfonylureas.

Gastric Emptying Delay as the Root of Pharmacokinetic Interactions

In healthy volunteers, a single 1.5 mg dose of dulaglutide reduced the rate of gastric emptying, decreasing mean acetaminophen Cmax by approximately 36% and delaying Tmax from 0.75 hours to 3.0 hours [3]. This effect attenuates with repeated weekly dosing as the receptor desensitizes, but it does not disappear entirely. Any oral drug with a narrow therapeutic index, a steep concentration-response curve, or time-sensitive absorption (such as rapid-acting analgesics or contraceptive hormones taken at peak absorption windows) may be affected during the first several weeks of dulaglutide initiation or dose escalation.

Pharmacokinetic Drug Interactions: Absorption-Phase Effects

Pharmacokinetic (PK) interactions with dulaglutide are almost exclusively absorption-phase effects driven by delayed gastric emptying. Dulaglutide does not inhibit or induce any major CYP450 enzymes, and it is not a substrate of CYP, P-glycoprotein, or organic anion transporters [4]. This means hepatic metabolism interactions are not a concern.

Oral Analgesics and Acetaminophen

Acetaminophen is routinely used as a gastric-emptying probe drug. The FDA-reviewed pharmacokinetic study embedded in the Trulicity prescribing information showed that co-administration with 0.75 mg dulaglutide reduced acetaminophen Cmax by 26% and extended Tmax from 0.75 to 2 hours [3]. At the 1.5 mg dose, Cmax fell by 36%. AUC was unchanged, meaning total drug exposure is preserved. For most patients, this delay is clinically insignificant. Patients using acetaminophen for acute pain who expect rapid onset may notice delayed effect during the first 4 to 6 weeks of dulaglutide use.

Oral Contraceptives

Dulaglutide's effect on ethinylestradiol and norgestimate pharmacokinetics was evaluated in a dedicated crossover study in healthy women. At steady-state dulaglutide 1.5 mg, ethinylestradiol AUC and Cmax were within 10% of baseline, and norgestimate metabolite (norelgestromin) AUC was also within acceptable bioequivalence bounds [3]. Contraceptive efficacy is not expected to be compromised. The FDA labeling does note that patients should take oral contraceptives at least 1 hour before or 4 hours after the dulaglutide injection if they want to further minimize any transient Cmax effect, though this timing instruction is precautionary rather than mandatory [3].

Digoxin

Digoxin is a narrow-therapeutic-index cardiac glycoside with non-linear pharmacokinetics. One published pharmacokinetic analysis found no clinically meaningful change in digoxin AUC or Cmax when co-administered with a GLP-1 agonist in steady-state conditions [5]. Monitoring of serum digoxin concentrations is nonetheless prudent at dulaglutide initiation and at dose escalation to 1.5 mg, because the attenuated gastric-emptying effect during early weeks could transiently alter Tmax in individual patients.

Atorvastatin

A pharmacokinetic sub-study co-administering atorvastatin 40 mg with dulaglutide 1.5 mg found atorvastatin Cmax decreased by 70% and Tmax increased from 1.0 to 4.0 hours, though AUC decreased by only about 21% [3]. The clinical significance of this interaction is uncertain given that statins are typically dosed in the evening and dulaglutide is injected on a fixed weekly day. Timing atorvastatin at least 1 hour before the dulaglutide injection is a practical precaution for patients who take both in the morning.

Lisinopril

A single co-administration pharmacokinetic study showed lisinopril Cmax fell by 15% and Tmax was delayed by 2 hours when co-administered with dulaglutide 1.5 mg [3]. The AUC of lisinopril was not significantly altered. For most patients with type 2 diabetes and hypertension taking both agents, this degree of Cmax reduction is unlikely to affect blood pressure control, since ACE inhibitors act through sustained trough concentrations rather than peak levels.

Pharmacodynamic Drug Interactions: Glycemic Risk

Pharmacodynamic (PD) interactions with dulaglutide are the most clinically consequential category. These occur when dulaglutide's glucose-lowering effect is additive or synergistic with another antidiabetic agent, increasing hypoglycemia risk beyond what either agent produces alone [6].

Insulin Co-Therapy

Combining dulaglutide with basal insulin (e.g., insulin glargine U-100 or insulin degludec) is an FDA-approved combination strategy used when basal insulin alone does not achieve glycemic targets [7]. The AWARD-9 trial (N=300) demonstrated that adding dulaglutide 1.5 mg weekly to insulin glargine produced an additional HbA1c reduction of 1.08 percentage points vs. Placebo at 28 weeks, but documented hypoglycemia rates were 36% in the dulaglutide group vs. 22% in the placebo group [8]. Clinical practice guidelines from the American Diabetes Association recommend reducing basal insulin by 10 to 20% when initiating a GLP-1 agonist in patients already at or near glycemic goal to prevent hypoglycemia [6].

Rapid-acting insulin combinations carry greater risk. Patients on basal-bolus regimens should monitor fasting and post-prandial glucose more frequently for the first 4 to 8 weeks after dulaglutide initiation or dose escalation. Structured self-monitoring protocols reduce severe hypoglycemia events.

Sulfonylureas

Sulfonylureas (e.g., glipizide, glimepiride, glyburide) stimulate insulin secretion independently of glucose. When added to dulaglutide, the glucose-dependent insulin release from GLP-1 agonism and the glucose-independent secretagogue effect of the sulfonylurea overlap, raising hypoglycemia risk substantially. The Trulicity prescribing information specifies that the sulfonylurea dose should be reduced when initiating dulaglutide [3]. In the AWARD-5 trial (N=1,098), dulaglutide 1.5 mg as monotherapy produced a lower symptomatic hypoglycemia rate than sitagliptin alone, but co-therapy data reinforce the need for pre-emptive sulfonylurea dose reduction of approximately 25 to 50% [9].

Meglitinides

Repaglinide and nateglinide share the insulin secretagogue mechanism of sulfonylureas but have shorter durations of action. The additive hypoglycemia risk exists but is time-limited to the meal period. Meal skipping while on dulaglutide plus a meglitinide is a notable hypoglycemia trigger. Dose reduction guidance mirrors the sulfonylurea recommendation.

Warfarin: A Special Interaction Case

Warfarin requires its own section because of the non-pharmacokinetic complexity involved. Warfarin anticoagulant effect (measured by INR) depends on vitamin K intake from food and warfarin absorption, both of which can be affected by gastric motility changes [10].

INR Variability Mechanism

When dulaglutide delays gastric emptying, it slows both warfarin tablet dissolution and the rate of dietary vitamin K absorption from concurrent meals. Either effect can shift INR unpredictably in the first weeks of dulaglutide use. A retrospective case series published in the pharmacotherapy literature identified INR elevations of 0.5 to 1.5 INR units in patients started on GLP-1 agonists without warfarin dose adjustment [10].

Monitoring Recommendation

The FDA label for dulaglutide recommends more frequent INR monitoring after dulaglutide initiation and after each dose escalation in warfarin-anticoagulated patients [3]. Practically, this means checking INR at 1 week and 3 weeks post-initiation, then resuming the patient's usual monitoring interval once stability is confirmed. Warfarin dose adjustment based on INR trend, rather than preemptive fixed-dose reduction, is the standard approach.

Drugs That Interact With Dulaglutide Through Glucose Counter-Regulation

Several non-antidiabetic drug classes can impair the counter-regulatory response to hypoglycemia or directly antagonize glucose lowering, creating a pharmacodynamic interaction that runs in the opposite direction from the insulin/sulfonylurea concern.

Beta-Blockers

Non-selective beta-blockers (e.g., propranolol, carvedilol) blunt tachycardia, the earliest warning sign of hypoglycemia. In patients on dulaglutide plus insulin or a sulfonylurea, concurrent beta-blocker use increases the risk of unrecognized hypoglycemia. Selective beta-1 blockers (e.g., metoprolol succinate) carry lower risk but are not fully protective. Patients should be counseled that sweating remains a reliable hypoglycemia symptom even when beta-blockers mask the heart rate response [6].

Corticosteroids

Systemic corticosteroids (e.g., prednisone 20 mg daily) can raise fasting glucose by 40 to 80 mg/dL and post-prandial glucose substantially more, counteracting dulaglutide's glucose-lowering effect [11]. Short corticosteroid bursts (3 to 5 days) used for asthma or inflammatory conditions often require short-term upward adjustment of the patient's antidiabetic regimen. Because dulaglutide is a weekly injectable, it cannot be rapidly titrated to match the day-to-day glucose changes during a corticosteroid taper. Supplemental oral or injectable rapid-acting insulin is the preferred bridge during high-dose steroid courses.

Thiazide Diuretics

Thiazides (e.g., hydrochlorothiazide, chlorthalidone) cause modest hyperglycemia through potassium depletion impairing insulin secretion and through direct effects on glucose transport [12]. The magnitude is generally 2 to 5 mg/dL fasting glucose increase at standard antihypertensive doses, which is unlikely to require GLP-1 agonist dose adjustment. Monitoring fasting glucose within 6 to 8 weeks of adding or increasing a thiazide is a reasonable precaution.

Antipsychotics

Second-generation antipsychotics (SGAs), particularly olanzapine and clozapine, cause weight gain, insulin resistance, and direct impairment of glucose-stimulated insulin secretion [13]. In patients on dulaglutide for glycemic control who are also prescribed an SGA, weight gain from the antipsychotic may partially offset the weight-reduction effect of dulaglutide (mean weight loss with dulaglutide 1.5 mg: approximately 3 kg at 26 weeks in AWARD-5 [9]). Glycemic targets may be harder to reach; the dose may need to be escalated to 3 mg or 4.5 mg in patients on the extended-dose versions now available.

Cardiovascular Context: The REWIND Trial and Interaction-Relevant Polypharmacy

The REWIND trial enrolled 9,901 adults with type 2 diabetes (mean age 66 years, 46% women) who had established cardiovascular disease or multiple risk factors. Participants were randomized to dulaglutide 1.5 mg weekly or placebo on top of standard care. At a median follow-up of 5.4 years, dulaglutide reduced the primary composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death by 12% (HR 0.88, 95% CI 0.79 to 0.99, P = 0.026) [14].

Polypharmacy in REWIND Participants

REWIND participants were heavily medicated at baseline: 81% were on statins, 84% on ACE inhibitors or ARBs, and 52% on aspirin [14]. This real-world polypharmacy burden makes REWIND the most interaction-relevant cardiovascular outcomes trial for dulaglutide. The observed cardiovascular benefit was consistent across subgroups stratified by background antidiabetic therapy, supporting that interaction-driven PK changes did not meaningfully erode efficacy in this setting.

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit should be considered independent of baseline HbA1c" [6].

Drug Interactions Specific to Cardiovascular Co-Medications

For patients on dulaglutide in the REWIND population profile, three interaction pairs deserve explicit attention at each medication review:

1. Dulaglutide plus aspirin: no pharmacokinetic interaction; the gastric-mucosal protective effect of slowed emptying may theoretically reduce GI aspirin irritation, though this has not been studied prospectively.
2. Dulaglutide plus ACE inhibitors: see lisinopril data above; no clinically significant PK interaction at steady state.
3. Dulaglutide plus statin: atorvastatin Cmax reduction of 70% when co-administered simultaneously, but AUC reduction is modest (21%); evening statin dosing eliminates even this minor concern [3].

Special Populations and Drug Interactions

Renal Impairment

Dulaglutide is not renally cleared, but renal impairment is common in patients with type 2 diabetes and changes the pharmacokinetics of many co-administered drugs. Metformin, which is frequently co-prescribed with dulaglutide, is contraindicated when eGFR falls below 30 mL/min/1.73m² [15]. The interaction between dulaglutide and metformin is not pharmacokinetic; they act through complementary mechanisms. However, clinicians managing patients on both drugs in declining renal function need to discontinue or reduce metformin before dulaglutide becomes the sole agent, which may precipitate the need to add other glucose-lowering drugs with their own interaction profiles.

Hepatic Impairment

Clinical pharmacology data from Lilly show no clinically relevant change in dulaglutide AUC or Cmax in patients with mild to moderate hepatic impairment [3]. The interactions with hepatically metabolized drugs (warfarin via CYP2C9, statins via CYP3A4, oral contraceptives via CYP3A4) remain driven by the gastric-emptying effect, not by any change in dulaglutide's own hepatic handling.

Older Adults

Adults aged 65 and older are more likely to be on polypharmacy regimens that include narrow-therapeutic-index drugs. A 2022 analysis published in Diabetes Care found that GLP-1 agonist-naive older adults (mean age 72 years) initiating these agents while on warfarin had a 2.1-fold higher rate of INR monitoring visits in the 60 days following initiation, reflecting real-world clinical response to the acknowledged interaction [16]. Prescribers should explicitly review the medication list for warfarin, digoxin, and sulfonylureas before initiating dulaglutide in patients over 65.

Practical Management Framework for Interaction Risk

The following stepwise approach applies at the point of prescribing dulaglutide:

Step 1. Medication reconciliation. Identify all current antidiabetic agents, anticoagulants, narrow-therapeutic-index drugs, and time-sensitive oral medications before writing the first prescription.

Step 2. Antidiabetic dose adjustment. Reduce sulfonylurea dose by 25 to 50% at dulaglutide initiation. If the patient is on basal insulin near glycemic goal, reduce insulin by 10 to 20% [6].

Step 3. Timing instructions for oral drugs. For oral medications with documented Cmax sensitivity (atorvastatin, lisinopril, oral contraceptives), counsel patients to take these at least 1 hour before the dulaglutide injection when both are taken in the morning, or to shift statin dosing to the evening.

Step 4. INR monitoring schedule. For warfarin-anticoagulated patients, check INR at 1 week and 3 weeks after dulaglutide initiation and after escalation from 0.75 mg to 1.5 mg.

Step 5. Follow-up glucose review. Schedule a 4-week follow-up call or visit to review fasting glucose logs and identify hypoglycemia patterns, particularly in patients on beta-blockers who may not perceive the full adrenergic symptom burden.

How Dulaglutide Compares With Other GLP-1 Agonists on Interaction Risk

Not all GLP-1 agonists carry the same interaction profile. Semaglutide 2.4 mg (Wegovy) produced larger Cmax reductions for co-administered drugs than dulaglutide in head-to-head pharmacokinetic modeling, likely because its gastric-emptying delay is more pronounced at higher doses [17]. Exenatide twice-daily has a shorter half-life and its gastric-emptying effect is concentrated in the 2-hour post-injection window, creating a narrow but potentially sharper PK interaction window compared with dulaglutide's sustained weekly exposure.

Dulaglutide's gastric-emptying effect is intermediate among GLP-1 agonists. In a crossover pharmacokinetic comparison, dulaglutide 1.5 mg slowed acetaminophen Tmax by approximately 2 hours, while semaglutide 1 mg delayed Tmax by approximately 3 hours in comparable study designs [17]. This places dulaglutide toward the lower end of gastric-emptying-mediated interaction risk within the class.